LTS:0QYQ (USA)
Business Description
Gilead Sciences Inc
NAICS : 325412
SIC : 2834
333 Lakeside Drive, Foster, CA, USA, 94404
Compare
Compare
Traded in other countries / regions
GILD.Argentina
•
GILD.Austria
•
GILD34.Brazil
•
GILD.Chile
•
GIS.Germany
•
GILD.Italy
•
GILD.Mexico
•
GILD.Peru
•
GILD.Switzerland
•
0QYQ.UK
•
GILD.USA
Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 1.3 | |||||
| Debt-to-EBITDA | 3.04 | |||||
| Interest Coverage | 7.6 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.3 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.5 | |||||
| 3-Year EBITDA Growth Rate | 4.4 | |||||
| 3-Year EPS without NRI Growth Rate | 5.7 | |||||
| 3-Year FCF Growth Rate | 14.4 | |||||
| 3-Year Book Growth Rate | 0.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 18.26 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -2.43 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.6 | |||||
| 9-Day RSI | 57.69 | |||||
| 14-Day RSI | 55.51 | |||||
| 6-1 Month Momentum % | 0.77 | |||||
| 12-1 Month Momentum % | -10.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | |||||
| Quick Ratio | 1.27 | |||||
| Cash Ratio | 0.61 | |||||
| Days Inventory | 87.41 | |||||
| Days Sales Outstanding | 56.01 | |||||
| Days Payable | 33.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.61 | |||||
| Dividend Payout Ratio | 0.88 | |||||
| 3-Year Dividend Growth Rate | 7.6 | |||||
| Forward Dividend Yield % | 4.67 | |||||
| 5-Year Yield-on-Cost % | 7.16 | |||||
| 3-Year Average Share Buyback Ratio | 0.7 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.59 | |||||
| Operating Margin % | 26.74 | |||||
| Net Margin % | 15.04 | |||||
| ROE % | 20.2 | |||||
| ROA % | 6.29 | |||||
| ROIC % | 9.92 | |||||
| ROC (Joel Greenblatt) % | 124.23 | |||||
| ROCE % | 11.67 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.2 | |||||
| Forward PE Ratio | 9.4 | |||||
| PE Ratio without NRI | 19.2 | |||||
| Shiller PE Ratio | 10.59 | |||||
| Price-to-Owner-Earnings | 19.25 | |||||
| PS Ratio | 2.89 | |||||
| PB Ratio | 3.9 | |||||
| Price-to-Free-Cash-Flow | 8.44 | |||||
| Price-to-Operating-Cash-Flow | 7.86 | |||||
| EV-to-EBIT | 15.26 | |||||
| EV-to-Forward-EBIT | 11.26 | |||||
| EV-to-EBITDA | 11.53 | |||||
| EV-to-Forward-EBITDA | 8.93 | |||||
| EV-to-Revenue | 3.61 | |||||
| EV-to-Forward-Revenue | 3.99 | |||||
| EV-to-FCF | 10.56 | |||||
| Price-to-Projected-FCF | 0.73 | |||||
| Price-to-Median-PS-Value | 0.74 | |||||
| Earnings Yield (Greenblatt) % | 6.55 | |||||
| Forward Rate of Return (Yacktman) % | -4.32 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 27,515 | ||
| EPS (TTM) ($) | 3.28 | ||
| Beta | 0.14 | ||
| Volatility % | 21.79 | ||
| 14-Day RSI | 55.51 | ||
| 14-Day ATR ($) | 0.973488 | ||
| 20-Day SMA ($) | 61.33925 | ||
| 12-1 Month Momentum % | -10.66 | ||
| 52-Week Range ($) | 57.202 - 73.96 | ||
| Shares Outstanding (Mil) | 1,253.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gilead Sciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||